ReviewVaccine2015
HIV vaccine-induced sero-reactivity: a challenge for trial participants, researchers, and physicians.
Review in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Descriptions of risks and benefits of HIV vaccine trials in low-and middle-income countries (LMICs): an integrative review.BMC medical ethics · 2025Pooled it
- Trial
- Sexual Behaviours and Practices before and after Phase I/II HIV Vaccine Trial: A Qualitative Study among Volunteers in Dar es Salaam Tanzania.International journal of environmental research and public health · 2020Trial
- Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or Polyphosphazene.The Journal of infectious diseases · 2016Trial
- The Influence of Community Members on Participation by Youth in an HIV Vaccine Trial in Tanzania.PloS one · 2016Trial
- Human immunodeficiency virus vaccines: Advances, challenges and future perspectives.World journal of virology · 2026Review
- Distinguishing active HIV-1 infection from vaccine-induced seropositivity in HIV vaccine trial participants.Science advances · 2025Article
- Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand.Open forum infectious diseases · 2025Article
- Perceptions and Acceptance of a Prophylactic Vaccine for Human Immunodeficiency Virus (HIV): A Qualitative Study.The patient · 2024Article
- HIV Diagnostics and Vaccines: It Takes Two to Tango.The Journal of infectious diseases · 2024Review
- Towards Novel HIV-1 Serodiagnostic Tests without Vaccine-Induced Seroreactivity.Microbiology spectrum · 2023Article
- Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants.PLOS global public health · 2023Article
- Vaccine-Induced Seroreactivity Impacts the Accuracy of HIV Testing Algorithms in Sub-Saharan Africa: An Exploratory Study.Vaccines · 2022Article
- "An Extra Variable to Consider"-Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical Trials.Journal of the Pediatric Infectious Diseases Society · 2022Article
- Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection.BMC medical ethics · 2021Article
- Shifts in UNAIDS ethics guidance and implications for ethics review of preventive HIV vaccine trials.Journal of the International AIDS Society · 2021Review
- An HIV Diagnostic Testing Algorithm Using the cobas HIV-1/HIV-2 Qualitative Assay for HIV Type Differentiation and Confirmation.Journal of clinical microbiology · 2021Article
- Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees.Open forum infectious diseases · 2021Article
- Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials.Journal of acquired immune deficiency syndromes (1999) · 2020Article
- HIV serology false positivity among expatriates from Africa: a screening dilemma.Journal of medical microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 10 institutions in 3 countries.
Funding
Abstract
Antibody-inducing vaccines are a major focus in the preventive HIV vaccine field. Because the most common tests for HIV infection rely on detecting antibodies to HIV, they may also detect antibodies induced by a candidate HIV vaccine. The detection of vaccine-induced antibodies to HIV by serological tests is most commonly referred to as vaccine-induced sero-reactivity (VISR). VISR can be misinterpreted as a sign of HIV infection in a healthy study participant. In a participant who has developed vaccine-induced antibodies, accurate diagnosis of HIV infection (or lack thereof) may require specialized tests and algorithms (differential testing) that are usually not available in community settings. Organizations sponsoring clinical testing of preventive HIV vaccine candidates have an ethical obligation not only to inform healthy volunteers about the potential problems associated with participating in a clinical trial but also to help manage any resulting issues. This article explores the scope of VISR-related issues that become increasingly prevalent as the search for an effective HIV vaccine continues and will be paramount once a preventive vaccine is deployed. We also describe ways in which organizations conducting HIV vaccine trials have addressed these issues and outline areas where more work is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.